MONALEESA-7 [108] investigated ribociclib in combination with endocrine therapy for early-stage HR+/HER2- breast cancer in premenopausal and perimenopausal women, showing a substantial increase in progression-free survival and overall survival. Here, ERBB2 is linked to breast cancer.